Dr. Reddy's Laboratories profit and loss

Latest FY26

Revenue: ₹33,700cr+3.2% on FY25
EBITDA: ₹6,454cr−24.5% on FY25
Net profit: ₹4,158cr−27.4% on FY25
EPS: ₹50.41−25.7% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	33,097	33,700	32,644	28,011	24,670	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	1,255	1,358	1,097	894	1,056
	34,353	35,059	33,741	28,905	25,725
	6,339	6,501	5,684	4,490	4,220
	6,711	6,162	4,841	4,399	3,367
	−189	−424	−545	−681	70.9
	6,299	5,991	5,580	5,030	4,647
	450	374	283	171	143
	2,141	2,059	1,704	1,470	1,250
	9,077	9,017	8,537	6,839	6,016
	30,829	29,679	26,083	21,719	19,714
	4,861	6,454	8,547	7,933	6,349
	2,719	4,395	6,843	6,463	5,099
Profit
	3,524	5,379	7,658	7,186	6,012
	3,524	5,379	7,658	7,186	6,012
	646	1,395	2,258	1,946	814
	118	−159	−304	−323	727
	764	1,235	1,954	1,623	1,541
	0.0	13.4	21.7	14.7	37.0
	2,760	4,158	5,725	5,578	4,507
	2,760	4,144	5,704	5,563	4,470
	582	740	205	−65.6	−12.1
	3,341	4,897	5,930	5,512	4,495
	2,800	4,196	5,655	—	4,507
	−40.2	−38.4	70.1	0.0	—
Per share
	₹33.61	₹50.41	₹67.89	₹335.22	₹271.47
	₹33.59	₹50.35	₹67.79	₹334.59	₹270.90
Other comprehensive income — detail
	582	740	205	−65.6	−12.1
	13.2	14.3	−29.3	−2.8	−66.0
	5.4	5.6	−2.4	−0.4	4.3
	—	5.6	−2.4	−0.4	4.3
	587	692	238	−74.9	27.6
	12.6	−39.2	5.8	−11.7	−30.6
	—	−39.2	5.8	−11.7	−30.6
	3,382	4,936	5,860	5,512	4,495
	−40.2	−38.4	70.1	0.0	0.0
Per share — as-filed variants
	₹33.61	₹50.41	₹67.89	₹335.22	₹271.47
	₹33.59	₹50.35	₹67.79	₹334.59	₹270.90
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	20,236	21,461	22,664	19,802	17,012
	61.1%	63.7%	69.4%	70.7%	69.0%
Adjusted (ex-exceptional items) — derived
	3,524	5,379	7,658	7,186	6,012
	2,760	4,158	5,725	5,578	4,507
	₹33.61	₹50.41	₹67.89	₹335.22	₹271.47

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

DRREDDY₹1,335.40

Dr. Reddy's Laboratories Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersSUNPHARMA CIPLA LUPIN APOLLOHOSP MAXHEALTH DIVISLAB TORNTPHARM ZYDUSLIFEMcap ₹1.12L Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Revenue from Operations	24,669.7	28,011.1	32,643.9	33,700.2	33,097.4
Other Income	1,055.5	894.3	1,097.3	1,358.4	1,255.1
Total Income	25,725.2	28,905.4	33,741.2	35,058.6	34,352.5
Expenses
+ Cost of Materials Consumed	4,219.8	4,490.1	5,683.5	6,501.2	6,338.9
+ Purchases of Stock-in-Trade	3,367.0	4,399.1	4,841.1	6,161.6	6,711.1
+ Changes in Inventories	70.9	-680.5	-544.7	-423.6	-188.8
+ Employee Benefit Expense	4,646.6	5,030.1	5,580.0	5,990.9	6,298.8
+ Finance Costs	142.8	171.1	282.9	373.8	450.4
+ Depreciation & Amortisation	1,250.2	1,470.0	1,703.7	2,058.8	2,141.4
+ Other Expenses	6,016.4	6,839.2	8,536.9	9,016.6	9,076.9
Total Expenses	19,713.7	21,719.1	26,083.4	29,679.3	30,828.7
EBITDA	6,349.0	7,933.1	8,547.1	6,453.5	4,860.5
EBIT	5,098.8	6,463.1	6,843.4	4,394.7	2,719.1
Profit
PBT before Exceptional Items	6,011.5	7,186.3	7,657.8	5,379.3	3,523.8
Pretax Income	6,011.5	7,186.3	7,657.8	5,379.3	3,523.8
+ Current Tax	814.4	1,945.9	2,258.1	1,394.5	646.4
+ Deferred Tax	726.8	-322.8	-303.8	-159.4	117.7
Tax Expense	1,541.2	1,623.1	1,954.3	1,235.1	764.1
+ Share of Associates & JVs	37.0	14.7	21.7	13.4	0.0
Net Income	4,507.3	5,577.9	5,725.2	4,157.6	2,759.7
+ Net Income — Continuing Ops	4,470.3	5,563.2	5,703.5	4,144.2	2,759.7
+ Other Comprehensive Income	-12.1	-65.6	204.9	739.5	581.7
Total Comprehensive Income	4,495.2	5,512.3	5,930.1	4,897.1	3,341.4
Net Income to Common	4,507.3	—	5,655.1	4,196.0	2,799.9
Minority Interest	—	0.0	70.1	-38.4	-40.2
Per Share
Basic EPS	271.47	335.22	67.89	50.41	33.61
Diluted EPS	270.90	334.59	67.79	50.35	33.59
Other Comprehensive Income — detail
+ Other Comprehensive Income	-12.1	-65.6	204.9	739.5	581.7
+ Items NOT to be Reclassified to P&L	-66.0	-2.8	-29.3	14.3	13.2
+ Tax on Items NOT to be Reclassified	4.3	-0.4	-2.4	5.6	5.4
+ Tax on Items NOT to be Reclassified — alt tag	4.3	-0.4	-2.4	5.6	—
+ Items to be Reclassified to P&L	27.6	-74.9	237.6	691.6	586.5
+ Tax on Items to be Reclassified	-30.6	-11.7	5.8	-39.2	12.6
+ Tax on Items to be Reclassified — alt tag	-30.6	-11.7	5.8	-39.2	—
Comprehensive Income — Owners of Parent	4,495.2	5,512.3	5,860.0	4,935.5	3,381.6
Comprehensive Income — Non-controlling Interests	0.0	0.0	70.1	-38.4	-40.2
Per Share — as-filed variants
Basic EPS — Continuing Operations	271.47	335.22	67.89	50.41	33.61
Diluted EPS — Continuing Operations	270.90	334.59	67.79	50.35	33.59
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	17,012.0	19,802.4	22,664.0	21,461.0	20,236.2
Gross Margin %	68.96	70.69	69.43	63.68	61.14
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	6,011.5	7,186.3	7,657.8	5,379.3	3,523.8
Net Income Adj (tax-effected)	4,507.3	5,577.9	5,725.2	4,157.6	2,759.7
EPS Adj	271.47	335.22	67.89	50.41	33.61
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	5.00	—	1.00	1.00	1.00
Paid Up Equity Capital	83.3	83.4	83.4	83.5	83.5

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.